New insights into glucose regulation

Diabetes Educator

Volumn 32, Issue 2, 2006, Pages 221-228

  Kruger, Davida F ^a   Martin, Catherine L ^b   Sadler, Christopher E ^c  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Diabetes and Endocrine Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

DIABETES MELLITUS; DIET RESTRICTION; EATING; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS; EATING; FASTING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEOSTASIS; HUMANS;

EID: 33645302132     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721706286568     Document Type: Review

References (53)

1. Aronoff SL, Berkowitz K, Schreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17:183-190.
2. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142:521-527.
3. Samson M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol. 2000;278:G946-G951.
4. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954-1962.
5. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66:91-103.
6. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp Clin Endocrinol Diabetes. 1997;105:187-195.
7. Perfetti R, Merkel P. Glucagon-like peptide-1 : a major regulator of pancreatic, β cell function. Eur J Endocrinol. 2000;143:717-725.
8. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.
9. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830.
10. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes. 2001;50:1720-1728.
11. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72.
12. Drucker DJ. Glucagon-like peptides: regulation of cell proliferation, differentiation and apoptosis. Mol Endocrinol. 2003;17:161-171.
13. Gerich JE, Schneider V, Dippe SE, et al. Characterization of the glucagon response to hypoglycemia in man. J Clin Endocrinol Metab. 1974;38:77-82.
14. Wallum BJ, Kahn SE, McCulloch DK, Porte D. Insulin secretion in the normal and diabetic human. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. Chichester, UK: John Wiley & Sons; 1992:285-301.
15. Lefebvre PJ. Glucagon and its family revisited. Diabetes Care. 1995;18:715-730.
16. Cryer PE. Glucose homeostasis and hypoglycaemia. In: Wilson JD, Foster DW, eds. William's Textbook of Endocrinology. Philadelphia, Pa: W. B. Saunders Company; 1992:1223-1253.
17. Gerich JE. Control of glycaemia. Baillieres Best Pract Res Clin Endocrinol Metab. 1993;7:551-586.
18. Cryer, PE. Hypoglycemia: The limiting factor in the management of IDDM. Diabetes. 1994;43:1378-1389.
19. Cooper GJS, Willis AC, Clark A, Turner RD, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987;84:8628-8632.
20. Moore CX, Cooper GJS. Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycaemic agents. Biochem Biophys Res Commun. 1991;179:1-9.
21. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest. 1990;85:973-976.
22. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet. 1992;339:1179-1180.
23. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes: relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest. 1984;74:985-991.
24. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997;46:67-70.
25. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol. 1997;11:167-239.
26. Beeley NRA, Prickett KS. The amylin, CGRP and calcitonin family of peptides. Expert Opin Therapeut Patents. 1996;6:555-567.
27. Van Rossum D, Menard DP, Fournier A, St Pierre S, Quirion R. Autoradiographic distribution and receptor binding profile of (1-125) Bolton Hunter-rat amylin binding sites in the rat brain. J Pharmacol Exp Ther. 1994;270:779-787.
28. Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. Mol Pharmacol. 1993;44:493-497.
29. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7:1353-1373.
30. Heise T, Heinemann L, Heller S, et al. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism. 2004;53:1227-1232.
31. Bhavsar S, Watkins J, Young AA. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav. 1998;64:557-561.
32. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850-853.
33. Rushing PA, Hagan MM, Seeley RJ. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology. 2001;142:5035-5038.
34. Cryer PE. Glucose counterregulation in man. Diabetes. 1981;30:261-264.
35. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM. Diabetologia. 1995;38:337-343.
36. Kruger DF, Gatcombe PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389-397.
37. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.
38. Lugari R, Dei Cas A, Ugolotti D, et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2002;34:150-154.
39. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857-862.
40. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723.
41. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331:1428-1436.
42. Kahn SE. The importance of the beta cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108:2S-8S.
43. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
44. Garber A, Marre M, Blonde L, et al. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. Diabetes Obes Metab. 2003;5:171-179.
45. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type 2 diabetes: a progressive disease (UKPDS 16). Diabetes. 1995;44:1249-1258.
46. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
47. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
48. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
49. Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 1999;48:99-105.
50. Heinemann L, Heise T, Wahl LC, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996;13:625-629.
51. Jacobs MA, Keulen ET, Kanc K, et al. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care. 1997;20:1279-1286.
52. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27:1265-1270.
53. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care. 1996;19:744-750.